

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 8-K

**CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): February 17, 2026

TURN THERAPEUTICS INC.
(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation)	001-42875 (Commission File Number)	32-0456090 (IRS Employer Identification Number)
250 N. Westlake Blvd., Westlake Village, California (Address of principal executive offices)		91362 (Zip Code)

Registrant's telephone number, including area code: **(818) 564-4011**

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class	Trading Symbol	Name of Each Exchange on Which Registered
Common Stock, par value \$0.0001 per share	TTRX	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 7.01 Regulation FD Disclosure.

On February 17, 2026, the Company issued a press release (the “Press Release”). The Press Release is furnished herewith as Exhibit 99.1.

The information in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, unless the Company specifically states that the information is to be considered “filed” under the Exchange Act or specifically incorporates it by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act.

Item 9.01 Financial Statements and Exhibits.**(d) Exhibits**

Exhibit No.	Description
99.1	Press Release dated February 17, 2026
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 17, 2026

TURN THERAPEUTICS INC.

By: /s/ Bradley Burnam

Name: Bradley Burnam

Title: Chief Executive Officer



**Turn Therapeutics Appoints Dr. Robert Redfield as
Senior Advisor of Health Policy and Regulatory Affairs**

Nationally recognized public health leader and former Director of the CDC to provide strategic guidance on GX-03 development, the company's lead investigational therapy

LOS ANGELES — February 17, 2026 — Turn Therapeutics, Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunology therapies for dermatologic conditions, today announced the appointment of Robert Redfield, M.D., as Senior Advisor of Health Policy and Regulatory Affairs. In this role, Dr. Redfield will provide strategic guidance on clinical development, public health implications, and regulatory positioning of the company's lead investigational therapy, GX-03, which is currently in Phase 2 clinical trials.

"Dr. Redfield brings an incomparable level of experience, public health insight, and regulatory knowledge to the Turn ecosystem," said Brad Burnam, Chief Executive Officer of Turn Therapeutics. "As we advance GX-03 through mid-stage clinical development, his guidance will be instrumental in accelerating our regulatory path to patients."

Dr. Redfield is a nationally recognized virologist and public health leader who served as the 18th Director of the U.S. Centers for Disease Control and Prevention (CDC) and as Administrator of the Agency for Toxic Substances and Disease Registry from 2018 to 2021. During his tenure, he oversaw the nation's response to major public health challenges and led efforts to strengthen scientific rigor, surveillance, and translational impact across federal health agencies. He earned a Bachelor of Science from Georgetown University's College of Arts and Sciences and received his Doctor of Medicine from Georgetown University School of Medicine.

Dr. Redfield stated, "Turn Therapeutics is pursuing a scientifically rigorous approach to addressing important unmet needs for large populations with few safe and effective options. I look forward to contributing my experience in clinical and regulatory policy to support the rapid advancement of GX-03."

About Turn Therapeutics

Turn Therapeutics is a biotechnology company focused on developing innovative, precision therapies that target the underlying causes of inflammatory diseases with high unmet needs. Their lead investigational therapy, GX-03, is a first-in-class, non-systemic topical inhibitor currently in late-stage development for the treatment of moderate-to-severe atopic dermatitis (eczema). This therapy is designed to modulate key inflammatory pathways involved in eczema and other inflammatory dermatological conditions.

Forward-Looking Statement

Certain statements in this press release may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "suggest," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Turn's current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict, including risks related to the timing and effectiveness of the Company's registration statement, the success of development programs, and the Company's ability to execute its strategic plan. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Turn Therapeutics in general, see the risk disclosures in the Company's filings with the SEC. All such forward-looking statements speak only as of the date they are made, and Turn undertakes no obligation to update or revise these statements, whether as a result of new information, future events, or otherwise.

Investor Relations/Media Contact:

Sasha Damouni
Damouni Group, LLC
Sasha@damounigroup.com